Form 4: ACAD CFO Schneyer Reports RSU Vesting, Tax-Related Stock Sales

Acadia Pharmaceuticals' CFO, Mark C. Schneyer, reported the vesting of restricted stock units and subsequent mandatory sales to cover tax obligations.

Summary

• Mark C. Schneyer, EVP, Chief Financial Officer of Acadia Pharmaceuticals Inc. (ACAD), reported transactions involving common stock.
• On March 24, 2026, 8,138 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• On March 25, 2026, 6,178 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Sales of 4,177 shares at $21.47, 3,171 shares at $21.65, and 37 shares at $21.7174 occurred on March 25 and March 26, 2026.
• These sales were mandatory to cover withholding taxes and tax-related items associated with the RSU vesting, in compliance with Rule 10b5-1(c).
• Following these transactions, Mark C. Schneyer beneficially owns 60,269 shares of common stock directly.
• Remaining unvested restricted stock units include 24,414 units (vesting in four equal annual installments starting March 24, 2026) and 12,358 units (vesting in four equal annual installments starting March 25, 2025).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there are sales, they are mandatory for tax purposes following RSU vesting, which itself is a positive sign of ongoing executive incentive and compensation.

Positives

• The vesting of restricted stock units indicates continued long-term incentive alignment between the CFO and shareholder interests.
• The transactions were executed under a Rule 10b5-1 plan, demonstrating a pre-arranged and compliant approach to insider stock transactions.

Negatives

• The sale of 7,385 shares of common stock, even if for tax purposes, reduces the direct beneficial ownership of the CFO.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are a common occurrence for executives in the biotechnology and pharmaceutical industries. This type of transaction is a standard component of executive compensation packages, designed to align management incentives with long-term shareholder value creation while also addressing immediate tax liabilities upon vesting.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a significant component of executive compensation is a standard practice across the pharmaceutical and broader technology sectors, similar to companies like Pfizer, Johnson & Johnson, or Amgen.
• The mandatory sale of shares to cover tax withholding upon RSU vesting is a common and expected mechanism, often executed under Rule 10b5-1 plans, which are widely adopted by executives at public companies to avoid accusations of insider trading.
• The vesting schedules (e.g., four equal annual installments) are typical for long-term incentive plans, comparable to those seen at peer companies, ensuring retention and performance alignment over several years.

Stakeholder Impact

• Shareholders: The transactions reflect routine executive compensation and tax management, with minimal direct impact on company operations or strategy. The CFO's continued beneficial ownership of a significant number of shares aligns his interests with shareholders.
• Employees: No direct impact on general employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Next Steps

• Continued vesting of the remaining 24,414 restricted stock units in four equal annual installments beginning March 24, 2026.
• Continued vesting of the remaining 12,358 restricted stock units in four equal annual installments beginning March 25, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The transactions are expected and do not signal a change in management's confidence or a significant shift in company fundamentals. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company analysis rather than this specific filing.

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sales, Executive Compensation, Mark C. Schneyer, CFO